PMID- 27450877
OWN - NLM
STAT- MEDLINE
DCOM- 20171025
LR  - 20220409
IS  - 1876-7591 (Electronic)
IS  - 1936-878X (Print)
IS  - 1876-7591 (Linking)
VI  - 10
IP  - 4
DP  - 2017 Apr
TI  - Prognostic Value of Myocardial Scarring on CMR in Patients With Cardiac 
      Sarcoidosis.
PG  - 411-420
LID - S1936-878X(16)30414-4 [pii]
LID - 10.1016/j.jcmg.2016.05.009 [doi]
AB  - OBJECTIVES: This study sought to perform a systematic review and meta-analysis to 
      understand the prognostic value of myocardial scarring as evidenced by late 
      gadolinium enhancement (LGE) on cardiac magnetic resonance (CMR) imaging in 
      patients with known or suspected cardiac sarcoidosis. BACKGROUND: Although CMR is 
      increasingly used for the diagnosis of cardiac sarcoidosis, the prognostic value 
      of CMR has been less well described in this population. METHODS: PubMed, Cochrane 
      CENTRAL, and metaRegister of Controlled Trials were searched for CMR studies 
      with >/=1 year of prognostic data. Primary endpoints were all-cause mortality and a 
      composite outcome of arrhythmogenic events (ventricular arrhythmia, implantable 
      cardioverter-defibrillator shock, sudden cardiac death) plus all-cause mortality 
      during follow-up. Summary effect estimates were generated with random-effects 
      modeling. RESULTS: Ten studies were included, involving a total of 760 patients 
      with a mean follow-up of 3.0 +/- 1.1 years. Patients had a mean age of 53 years, 
      41% were male, 95.3% had known extracardiac sarcoidosis, and 21.6% had known 
      cardiac sarcoidosis. The average ejection fraction was 57.8 +/- 9.1%. Patients with 
      LGE had higher odds for all-cause mortality (odds ratio [OR]: 3.06; p < 0.03) and 
      higher odds of the composite outcome (OR: 10.74; p < 0.00001) than those without 
      LGE. Patients with LGE had an increased annualized event rate of the composite 
      outcome (11.9% vs. 1.1%; p < 0.0001). CONCLUSIONS: In patients with known or 
      suspected cardiac sarcoidosis, the presence of LGE on CMR imaging is associated 
      with increased odds of both all-cause mortality and arrhythmogenic events.
CI  - Copyright (c) 2017 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Coleman, G Cameron
AU  - Coleman GC
AD  - Department of Medicine, University of Virginia, Charlottesville, Virginia.
FAU - Shaw, Peter W
AU  - Shaw PW
AD  - Department of Medicine, University of Virginia, Charlottesville, Virginia.
FAU - Balfour, Pelbreton C Jr
AU  - Balfour PC Jr
AD  - Department of Medicine, University of Virginia, Charlottesville, Virginia.
FAU - Gonzalez, Jorge A
AU  - Gonzalez JA
AD  - Department of Medicine, University of Virginia, Charlottesville, Virginia.
FAU - Kramer, Christopher M
AU  - Kramer CM
AD  - Department of Medicine, University of Virginia, Charlottesville, Virginia; 
      Department of Radiology and Medical Imaging, University of Virginia, 
      Charlottesville, Virginia.
FAU - Patel, Amit R
AU  - Patel AR
AD  - Department of Medicine, University of Chicago Medicine, Chicago, Illinois; 
      Department of Radiology, University of Chicago Medicine, Chicago, Illinois.
FAU - Salerno, Michael
AU  - Salerno M
AD  - Department of Medicine, University of Virginia, Charlottesville, Virginia; 
      Department of Biomedical Engineering, University of Virginia, Charlottesville, 
      Virginia. Electronic address: ms5pc@virginia.edu.
LA  - eng
GR  - K23 HL112910/HL/NHLBI NIH HHS/United States
GR  - R01 HL131919/HL/NHLBI NIH HHS/United States
GR  - T32 EB003841/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160720
PL  - United States
TA  - JACC Cardiovasc Imaging
JT  - JACC. Cardiovascular imaging
JID - 101467978
RN  - 0 (Contrast Media)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
CIN - JACC Cardiovasc Imaging. 2017 Apr;10(4):421-423. PMID: 28385255
MH  - Adult
MH  - Aged
MH  - Cardiomyopathies/*diagnostic imaging/mortality/pathology/therapy
MH  - Chi-Square Distribution
MH  - Cicatrix/*diagnostic imaging/mortality/pathology/therapy
MH  - Contrast Media/administration & dosage
MH  - Female
MH  - Gadolinium/administration & dosage
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*pathology
MH  - Odds Ratio
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Factors
MH  - Sarcoidosis/*diagnostic imaging/mortality/pathology/therapy
MH  - Time Factors
PMC - PMC5237422
MID - NIHMS797995
OTO - NOTNLM
OT  - cardiac magnetic resonance
OT  - cardiac sarcoid
OT  - cardiovascular outcomes
OT  - late gadolinium enhancement
EDAT- 2016/07/28 06:00
MHDA- 2017/10/27 06:00
PMCR- 2018/04/01
CRDT- 2016/07/25 06:00
PHST- 2016/03/21 00:00 [received]
PHST- 2016/05/20 00:00 [revised]
PHST- 2016/05/25 00:00 [accepted]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/10/27 06:00 [medline]
PHST- 2016/07/25 06:00 [entrez]
PHST- 2018/04/01 00:00 [pmc-release]
AID - S1936-878X(16)30414-4 [pii]
AID - 10.1016/j.jcmg.2016.05.009 [doi]
PST - ppublish
SO  - JACC Cardiovasc Imaging. 2017 Apr;10(4):411-420. doi: 10.1016/j.jcmg.2016.05.009. 
      Epub 2016 Jul 20.